Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Diabetes Management

Evolution of insulin therapy – patients and practitioners benefit

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • RX
    • Studies
  • 4 minute read

In Switzerland, the first rapid-acting and long-acting insulin analogues came onto the market about twenty years ago. These have been successively developed further, so that today a wide range of preparations is available for personalized diabetes treatment. Diabetes technology innovations have also significantly improved insulin therapy and the quality of life of those affected. These include continuous glucose monitoring and the “Hybrid”/”closed-loop” systems with adaptive insulin delivery.

For people with diabetes, these achievements lead to greater autonomy and empowerment at all stages of life [1]. Despite all these developments, however, lifestyle measures such as regular exercise sessions and dietary changes remain a central component of diabetes therapy.

Ultrafast and ultra-long acting insulin analogues

Recent developments include ultrafast analogs that further reduce postprandial glucose spikes and accumulation-induced hypoglycemia by providing an even faster onset and offset of insulin action [1]. The latest ultra-long-acting basal insulins minimize hypoglycemia through longer duration of action and more stable action profiles. Nevertheless, to date it is not possible to fully simulate the physiological 3:1 ratio of insulin exposure of liver and peripheral tissues with subcutaneous insulin therapy. Alternatives such as oral or liver-specific insulins are currently being researched. Inhaled insulin is not approved in Switzerland.

Continuous glucose monitoring

In addition to conventional continuous glucose monitoring (CGM) systems that continuously send readings to a receiver device, there are also so-called “flash glucose monitoring” systems that require glucose values to be actively retrieved using a reader [1]. Glucose is measured in the subcutaneous adipose tissue using an enzyme-coated sensor. CGM/”Flash Glucose Monitoring” systems provide a dynamic glucose curve compared to conventional capillary blood glucose measurements. Studies have shown an improvement in glycemic control with a reduction in hypoglycemia, and clinical practice has shown that these systems have a positive impact on user motivation and self-management. Affected individuals can anticipate glucose deviations and take appropriate action. It is not only the diabetics themselves who benefit from the fact that therapy can be adjusted more precisely and situationally, but the entire treatment team.

“Closed-loop” systems and AI-assisted “decision support”.

The coupling of insulin pumps with CGM systems led to the development of so-called “closed-loop” systems [1]. These closed-loop systems enable automated and on-demand insulin delivery with the goal of improving glucose control. This reduces the amount of therapy required for those affected and thus leads to relief. While “Fully Closed-Loop” systems operate autonomously, “Hybrid Closed-Loop” systems require input from the user such as meal announcements. For some years now, various “hybrid closed-loop” systems have been commercially available in Switzerland and have been used with great success primarily in type 1 diabetes. In contrast, no fully closed-loop system is currently approved in Germany. However, the fact that these systems significantly improve glucose control in the inpatient setting, in (par)enteral nutrition, or in dialysis patients is considered empirically confirmed [2–4].

What future developments are emerging?

Regarding non-insulin antidiabetic agents, the combination of the gut hormones GLP-1 and GIP is being studied with potent effects on glucose control and weight loss [5]. In the field of insulin therapy, research is being conducted, among other things, on the development of even longer-acting insulin analogues, for example in the form of basic insulin applied once a week [6].  Closed-loop” systems are constantly being improved by equipping them with more precise CGM sensors, even faster-acting insulin analogues, the addition of hormones such as glucagon or amylin analogues (“multiple-hormone artificial pancreas”) or the integration of movement and nutrition data. In addition, they are trying to make the systems more and more user-friendly. Integrative data analysis can already benefit from artificial intelligence (AI) methods. The application of new technologies leads to the generation of increasingly large amounts of data. Complex patterns can be identified through the use of AI-powered methods. This is a basis for so-called “decision support” systems to support affected individuals and their treatment teams. Increasing digitization enables the development of telemedical applications that provide therapy recommendations to patients based on the collected data. Even if there are still certain regulatory and data protection hurdles with regard to AI and digitization, the future potential of these innovative technologies is enormous. Not only are further efforts underway in the field of diabetes technology and pharmacotherapy, but also research in islet cell transplantation continues, for example with encapsulated islet cells [1].

 

Literature:

  1. Lehmann V, et al.: Diabetes therapy in transition – evolution and revolution with focus on the affected. Swiss Med Forum 2022; 22(0506): 85-87.
  2. Bally L, et al: Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med 2018; 379(6): 547-56.
  3. Boughton CK, et al: Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7(5): 368-377.
  4. Boughton CK, et al: Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med 2021; 27(8): 1471-1476.
  5. Frías JP, et al: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385(6): 503-515.
  6. Rosenstock J, et al: Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 2020; 383(22): 2107-2116.

 

HAUSARZT PRAXIS 2022; 17(8): 34
CARDIOVASC 2022; 21(3): 32 

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • HAUSARZT PRAXIS
Related Topics
  • closed-loop
  • Diabetes
  • insulin therapy
Previous Article
  • Multiple sclerosis

Effective therapy management also protects brain volume

  • Congress Reports
  • Neurology
  • Pharmacology and toxicology
  • RX
View Post
Next Article
  • Shingles vaccination

Prevention of herpes zoster

  • CME continuing education
  • Education
  • General Internal Medicine
  • Infectiology
  • Partner Content
  • Prevention and health care
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 5 min
  • Anxiety disorders

New study on lavender oil extract in a long-term setting

    • RX
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • Psychiatry and psychotherapy
    • Studies
View Post
  • 12 min
  • Evidence, effectiveness and practical implications

Medicinal plants for allergic rhinitis

    • RX
    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • ORL
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • RX
    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
View Post
  • 6 min
  • Ventricular arrhythmias

Indication for ICD or WCD?

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Studies
View Post
  • 3 min
  • Early breast cancer

Overweight and obesity worsen the prognosis

    • Congress Reports
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis treatment with biologics

What are the latest trends?

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • Rheumatology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.